Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study
Authors:
Open Access
- 19 April 2017
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (6) , 2862-2866
Abstract
The receptor activator of nuclear factor κB (RANK) axis is the fundamental signaling pathway in bone formation as well as bone tumor pathophysiology. The aim of the present study was to evaluate the impact of the expression of RANK and its downstream signaling molecule Akt1 on tumor progression in patients with osteosarcoma. Expression of RANK and Akt1 was examined in 78 human osteosarcoma samples by immunohistochemistry using formalin-fixed samples. Following this, each graded immunohistochemistry result was correlated with clinicopathological parameters and patient survival. In total, 60 osteosarcomas (76.9%) expressed RANK and 58 cases (74.4%) showed expression of Akt1. In addition, expression of RANK was negatively correlated with disease-free survival by Kaplan-Meier analysis. A resistance was observed to chemotherapy in RANK-expressing cases, which was statistically significant (P<0.05). In addition, chemotherapy and staging of the tumor were found to independent factors that have an effect on patient survival (P<0.05). Thus, RANK was identified as a negative prognostic factor of osteosarcoma survival.Keywords
This publication has 21 references indexed in Scilit:
- Impact of RANK signalling on survival and chemotherapy response in osteosarcomaPathology, 2014
- RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcomaPediatric Blood & Cancer, 2010
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKLJournal of Bone and Mineral Research, 2009
- RANKL signaling in bone physiology and cancerCurrent Opinion in Supportive & Palliative Care, 2007
- Key roles of the OPG–RANK–RANKL system in bone oncologyExpert Review of Anticancer Therapy, 2007
- The RANK/RANKL/OPG triad in cancer-induced bone diseasesCancer and Metastasis Reviews, 2006
- Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc AdministrationJournal of Bone and Mineral Research, 2006
- Childhood Cancer Survival Trends in Europe: A EUROCARE Working Group StudyJournal of Clinical Oncology, 2005
- The protein kinase B/Akt signalling pathway in human malignancyCellular Signalling, 2002
- RANK is essential for osteoclast and lymph node developmentGenes & Development, 1999